222 related articles for article (PubMed ID: 31478993)
21. Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study.
Lin R; Wang Y; Huang F; Fan Z; Zhang S; Yang T; Xu Y; Xu N; Xuan L; Ye J; Sun J; Huang X; Liu Q
BMC Med; 2019 Aug; 17(1):156. PubMed ID: 31401973
[TBL] [Abstract][Full Text] [Related]
22. The early expansion of anergic NKG2A
Roberto A; Di Vito C; Zaghi E; Mazza EMC; Capucetti A; Calvi M; Tentorio P; Zanon V; Sarina B; Mariotti J; Bramanti S; Tenedini E; Tagliafico E; Bicciato S; Santoro A; Roederer M; Marcenaro E; Castagna L; Lugli E; Mavilio D
Haematologica; 2018 Aug; 103(8):1390-1402. PubMed ID: 29700172
[TBL] [Abstract][Full Text] [Related]
23. Calcineurin Inhibitors Replacement by Ruxolitinib as Graft-versus-Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation.
Zhao Y; Shi J; Luo Y; Gao F; Tan Y; Lai X; Yu J; Wei G; Huang H
Biol Blood Marrow Transplant; 2020 May; 26(5):e128-e133. PubMed ID: 31982545
[TBL] [Abstract][Full Text] [Related]
24. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
Zallio F; Primon V; Tamiazzo S; Pini M; Baraldi A; Corsetti MT; Gotta F; Bertassello C; Salvi F; Rocchetti A; Levis A
Clin Transplant; 2013; 27(4):E491-7. PubMed ID: 23781897
[TBL] [Abstract][Full Text] [Related]
25. Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow Transplantation.
Styczynski J; Tridello G; Gil L; Ljungman P; Hoek J; Iacobelli S; Ward KN; Cordonnier C; Einsele H; Socie G; Milpied N; Veelken H; Chevallier P; Yakoub-Agha I; Maertens J; Blaise D; Cornelissen J; Michallet M; Daguindau E; Petersen E; Passweg J; Greinix H; Duarte RF; Kröger N; Dreger P; Mohty M; Nagler A; Cesaro S
J Clin Oncol; 2016 Jul; 34(19):2212-20. PubMed ID: 27091716
[TBL] [Abstract][Full Text] [Related]
26. Low dose Rituximab for pre-emptive treatment of Epstein Barr virus reactivation after allogenic hematopoietic stem cell transplantation.
Delapierre B; Reman O; Dina J; Breuil C; Bellal M; Johnson-Ansah H; Gac AC; Damaj G; Chantepie S
Curr Res Transl Med; 2019 Nov; 67(4):145-148. PubMed ID: 30871955
[TBL] [Abstract][Full Text] [Related]
27. Epstein-Barr virus and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma: the prevalence and impacts on outcomes : EBV and CMV reactivation post allo-HCT in NHL.
Ding Y; Ru Y; Song T; Guo L; Zhang X; Zhu J; Li C; Jin Z; Huang H; Tu Y; Xu M; Xu Y; Chen J; Wu D
Ann Hematol; 2021 Nov; 100(11):2773-2785. PubMed ID: 34480615
[TBL] [Abstract][Full Text] [Related]
28. Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation.
Icheva V; Kayser S; Wolff D; Tuve S; Kyzirakos C; Bethge W; Greil J; Albert MH; Schwinger W; Nathrath M; Schumm M; Stevanovic S; Handgretinger R; Lang P; Feuchtinger T
J Clin Oncol; 2013 Jan; 31(1):39-48. PubMed ID: 23169501
[TBL] [Abstract][Full Text] [Related]
29. Quantity and Quality Reconstitution of NKG2A
Hu LJ; Zhao XY; Yu XX; Lv M; Han TT; Han W; Huang XJ
Biol Blood Marrow Transplant; 2019 Jan; 25(1):1-11. PubMed ID: 30142416
[TBL] [Abstract][Full Text] [Related]
30. Donor activating killer cell immunoglobulin-like receptors genes correlated with Epstein-Barr virus reactivation after haploidentical haematopoietic stem cell transplantation.
Wang X; Liu XF; Shang QN; Yu XX; Fan ZY; Cao XH; Huo MR; Chang YJ; Zhao XS; Wang Y; Zhang XH; Xu LP; Liu KY; Huang XJ; Zhao XY
Br J Haematol; 2022 Feb; 196(4):1007-1017. PubMed ID: 34787307
[TBL] [Abstract][Full Text] [Related]
31. Inverse correlation of Vδ2
Liu J; Bian Z; Wang X; Xu LP; Fu Q; Wang C; Chang YJ; Wang Y; Zhang XH; Jiang Z; Huang XJ
Br J Haematol; 2018 Jan; 180(2):276-285. PubMed ID: 29270985
[TBL] [Abstract][Full Text] [Related]
32. Donor NKG2C homozygosity contributes to CMV clearance after haploidentical transplantation.
Yu XX; Shang QN; Liu XF; He M; Pei XY; Mo XD; Lv M; Han TT; Huo MR; Zhao XS; Chang YJ; Wang Y; Zhang XH; Xu LP; Liu KY; Zhao XY; Huang XJ
JCI Insight; 2022 Feb; 7(3):. PubMed ID: 34990406
[TBL] [Abstract][Full Text] [Related]
33. Delay expression of NKp30 on NK cells correlates with long-term mycophenolate mofetil treatment and higher EBV viremia post allogenic hematological stem cells transplantation.
Yu XX; Cao XH; Yan H; Luo XY; Zhao XS; Sun YQ; Wang Y; Xu LP; Zhang XH; Chang YJ; Huang XJ; Zhao XY
Clin Immunol; 2019 Aug; 205():49-56. PubMed ID: 31112757
[TBL] [Abstract][Full Text] [Related]
34. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
[TBL] [Abstract][Full Text] [Related]
35. Clinical characteristics and outcomes of Epstein-Barr virus viral load after allogeneic hematopoietic stem cell transplantation.
Tsushima T; Masuda SI; Yoda N; Kainuma S; Kimeda C; Konno S; Tanaka K; Matsuo K; Shimoji S; Kimura K; Arai H; Utsu Y; Imadome KI; Aotsuka N
Ann Hematol; 2024 Mar; 103(3):935-946. PubMed ID: 38157001
[TBL] [Abstract][Full Text] [Related]
36. Risk Factors for and the Clinical Impact of Cytomegalovirus and Epstein-Barr Virus Infections in Pediatric Recipients of TCR-α/β- and CD19-Depleted Grafts.
Laberko A; Bogoyavlenskaya A; Shelikhova L; Shekhovtsova Z; Balashov D; Voronin K; Kurnikova E; Boyakova E; Raykina E; Brilliantova V; Pirumova V; Novichkova G; Maschan A; Maschan M
Biol Blood Marrow Transplant; 2017 Mar; 23(3):483-490. PubMed ID: 28039080
[TBL] [Abstract][Full Text] [Related]
37. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
38. Cutaneous graft-versus-host disease incidence is similar in haploidentical and matched unrelated hematopoietic transplant recipients: A retrospective cohort study.
Heberton MM; Tripathi S; Slade M; Trinkaus K; Romee R; Anadkat M
J Am Acad Dermatol; 2020 Dec; 83(6):1654-1658. PubMed ID: 31689447
[TBL] [Abstract][Full Text] [Related]
39. Regulation of Adaptive NK Cells and CD8 T Cells by HLA-C Correlates with Allogeneic Hematopoietic Cell Transplantation and with Cytomegalovirus Reactivation.
Horowitz A; Guethlein LA; Nemat-Gorgani N; Norman PJ; Cooley S; Miller JS; Parham P
J Immunol; 2015 Nov; 195(9):4524-36. PubMed ID: 26416275
[TBL] [Abstract][Full Text] [Related]
40. Association of Epstein-Barr virus reactivation with the recovery of CD4/CD8 double-negative T lymphocytes after haploidentical hematopoietic stem cell transplantation.
Bian Z; Liu J; Xu LP; Chang YJ; Wang Y; Zhang XH; Huang XJ
Bone Marrow Transplant; 2017 Feb; 52(2):264-269. PubMed ID: 27797369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]